10 Best Small-Cap Biotech Stocks to Buy According to Analysts

3. Janux Therapeutics, Inc. (NASDAQ:JANX)

Number of Hedge Fund Holders: 39

Upside Potential: 177.09%

Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the best small-cap biotech stocks to buy according to analysts.

On November 11, 2025, Jones Trading’s Soumit Roy reiterated his “Buy” rating on Janux Therapeutics, Inc. (NASDAQ:JANX), which reflects promising developments in the company’s prostate cancer program. The analyst highlighted the company’s mature data from its Phase 1 trials, which is expected to be released in the fourth quarter of 2025. This includes the company’s innovative T cell-engaging therapies, JANX007 and JANX008. Both therapies have seen significant progress in the prostate cancer space, with JANX007 being tested in earlier metastatic castration-resistant prostate cancer (mCRPC) settings. The total addressable market for these treatments is estimated at $10 billion in the U.S. alone.

Soumit Roy also highlighted the improved efficacy and durability of responses in the taxane-naïve setting, as shown through the promising preliminary data from JANX007. The analyst’s confidence was also boosted by Janux Therapeutics, Inc.’s (NASDAQ:JANX) healthy cash balance of $989 million as of the end of the third quarter.

Janux Therapeutics, Inc. (NASDAQ:JANX) reported its Q3 results on November 7, 2025, recording a net loss of $24.3 million, an improvement from $28.1 million in Q3 2024. The quarter marked strong momentum in its Phase 1 trials for its lead candidates, including T cell-engaging therapies, with preliminary data indicating enhanced efficacy and durability of responses. The company demonstrated disciplined cost management during the quarter, recording a reduction in general and administrative expenses despite an increase of $34.6 million in ongoing R&D investment.

Janux Therapeutics, Inc. (NASDAQ:JANX), a clinical-stage biopharmaceutical company, develops novel immunotherapies using its proprietary TRACTr and ARM platforms.